Clinical Applications for Single Cell Analysis Remain a Heavily Uncontested Market Place
Single cell genomic and proteomics tools have gained significant importance in the past 2 years. The year 2018 was particularly very active with a lot of platforms made available by both established life sciences tools companies and start-ups. 10X Genomics and Fluidigm have demonstrated the potential for high-throughput single cell applications. There is a constant quest for delivering the lowest cost per cell which is keeping the innovation curve high. Single cell technology developers continue to attract funds from venture capitalists, making it one of the attractive areas to invest in the life science industry. While advancements in the hardware side are addressing throughput and low cost per cell, complexity in the data analysis remains unaddressed, which leaves opportunities to develop analytical tools and bioinformatics pipeline for single cell analysis data. From an application standpoint, while most of the current applications for single cell analysis are restricted to translational research, biopharma applications present the second largest opportunity. Single cell analysis for clinical applications is a long-term opportunity and the company that focuses more on addressing this application will clearly gain the first-mover advantage.
This study analyzes the global single cell genomic and proteomic technologies and workflows and identifies key application areas and concepts that can help companies steer their way toward running a successful business. Documented insights from single cell biologists and researchers have been studied to identify current and future applications across translational, biopharma, clinical, and basic research. The study covers an assessment of the market across workflows, technologies, geographic regions, and applications. These assessments have been developed after carefully studying 23 companies that are currently offering and developing solutions for single cell isolation and analytical purposes.
Key Issues Addressed
- What is the future outlook for single cell technologies?
- What specific applications offer growth opportunities that can be leveraged by existing and future participants?
- What are the unmet needs and challenges in the single cell genomics and proteomics industry?
- What types of technologies (e.g., droplet based) are poised for growth?
- Who are the major companies offering high-, moderate-, and low-throughput solutions?
- What applications are driving the update of single cell genomic technologies?
- What are the strengths of companies offering single cell genomic and proteomic technologies?
- How will the structure of the market change over time? Is it ripe for acquisitions?
- How has the industry M&A evolved between various companies offering single cell genomics solutions?
- Where are the major themes of partnership?
- Who are the right customers/target audience for platforms?
- What do they want? What are they willing to pay?
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 10X Genomics
- 1CellBio
- Fluidigm
- Veridex
